TMS for Complex Regional Pain Syndrome
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to test whether Transcranial Magnetic Stimulation (TMS), which uses magnetic fields to stimulate nerve cells, can effectively reduce pain and other symptoms in people with Complex Regional Pain Syndrome (CRPS). The study includes two groups: one receives active TMS, while the other receives a sham (inactive) treatment, both administered once daily for two days. Researchers monitor participants to determine if symptoms improve and how long those improvements last. Suitable candidates for this trial are individuals diagnosed with CRPS for over three months who experience significant daily pain. As an unphased trial, this study provides a unique opportunity to explore a promising treatment option for CRPS.
Will I have to stop taking my current medications?
The trial protocol does not specify if you need to stop taking your current medications. However, if your medication use interferes with the study procedures or data integrity, the researcher may decide it is necessary.
What prior data suggests that TMS is safe for treating Complex Regional Pain Syndrome?
Research has shown that transcranial magnetic stimulation (TMS) is generally safe and well-tolerated. It already treats depression by targeting specific brain areas. Studies have found that TMS can also effectively treat pain linked to Complex Regional Pain Syndrome (CRPS).
Most patients handle TMS well, experiencing only minor side effects. Some may feel mild discomfort during the procedure, such as tingling or scalp sensitivity. Overall, TMS shows promise as a safe and effective way to manage CRPS symptoms.12345Why are researchers excited about this trial?
Transcranial Magnetic Stimulation (TMS) is unique because it targets the brain's pain-processing areas without the need for surgery or medication. Unlike standard treatments for Complex Regional Pain Syndrome, which often involve medication or invasive procedures, TMS uses magnetic fields to stimulate nerve cells, potentially offering a non-invasive and drug-free alternative. Researchers are excited about TMS because it may offer quicker relief and fewer side effects compared to traditional options, and it has the potential to be effective even in cases where other treatments have failed.
What evidence suggests that TMS might be an effective treatment for CRPS?
Research has shown that Transcranial Magnetic Stimulation (TMS) can help reduce pain in people with Complex Regional Pain Syndrome (CRPS). Early studies indicate that TMS can lower pain levels by 20-50% for some patients. One study reported a patient experiencing a 90% reduction in symptoms, including pain, after about 140 days. In this trial, participants will receive either active TMS in the target area or a sham treatment in a non-target area. TMS is already used to treat conditions like depression and certain types of pain, suggesting it could also be helpful for CRPS. It is important to note that TMS is an add-on therapy, used alongside other treatments for better results.46789
Are You a Good Fit for This Trial?
This trial is for adults aged 18-70 with Complex Regional Pain Syndrome (CRPS) for at least 3 months, who can perform required tasks and have a certain level of pain. It's not for those with psychological disorders, medical conditions or medications that affect the study, pregnant women, people in legal/disability claims, TMS contraindications like metal implants near stimulation site, epilepsy sufferers or those with MRI contraindications.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive TMS or sham treatment once daily for two days
Follow-up
Participants are monitored for safety and effectiveness after treatment until they reach baseline for two consecutive weeks
What Are the Treatments Tested in This Trial?
Interventions
- TMS
TMS is already approved in United States, European Union, Canada for the following indications:
- Depression
- Anxiety disorders
- Post-traumatic stress disorder (PTSD)
- Obsessive-compulsive disorder (OCD)
- Depression
- Anxiety disorders
- Post-traumatic stress disorder (PTSD)
- Obsessive-compulsive disorder (OCD)
- Depression
- Anxiety disorders
- Post-traumatic stress disorder (PTSD)
- Obsessive-compulsive disorder (OCD)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Stanford University
Lead Sponsor
Rocky Mountain Foundation
Collaborator
National Institutes of Health (NIH)
Collaborator
Redlich Pain Endowment
Collaborator
The Feldman Family Foundation Pain Research Fund
Collaborator